Glucagon(Xeris Pharmaceuticals, Inc.)

Anticipates full year 2025 total revenue of $292 million, exceeding the guidance range of $285-$290 million and reflecting growth of 44% compared to the prior year Expects fourth quarter and full year 2025 Recorlev® net revenue of $45 million and $139 million, respectively Full-year 2025 financial results and 2026 outlook planned for March 2, 2026 CHICAGO--(BUSINESS WIRE)--Jan. 8, 2026-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) today announced unaudited preliminary financial results for the fourth quarter and fiscal year 2025, and other highlights. "Our fourth quarter performance capped off a truly transformative 2025. Recorlev® delivered exceptional results, outperforming expectations and further strengthening the momentum our team built throughout the year,” said John Shannon, Chief Executive Officer. “When combined with the stellar contributions of Gvoke® and Keveyis®, we expect total revenue of approximately $292 million, exceeding the high end of our full-year 2025 guidance.” Shannon continued, “As we look ahead, we are incredibly excited about the opportunities before us. We enter the year with strong commercial momentum, supported by a robust balance sheet and a clear, disciplined strategy to fuel sustained, long-term, rapid growth across the business." Preliminary Full Year 2025 Highlights Recorlev® ended the year with approximately 700 patients on therapy, and our commercial expansion was executed according to plan. Gvoke® grew revenue more than 13% compared to the prior year. Keveyis® finished the year with a growing patient base and a greater number of patients on therapy compared to year-end 2024. Delivered positive Adjusted EBITDA in every quarter. Strengthened Xeris’ intellectual property portfolio with a new Orange Book-listed U.S. patent for Recorlev® and a composition of matter patent for XP-8121, reinforcing long-term protection across both commercial and pipeline assets. Presented long-term financial targets and a clear strategic vision to drive sustained growth and value creation during the Company’s first Analyst and Investor Day. About Xeris Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Recorlev®, for the treatment of endogenous Cushing’s syndrome; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, as well as multiple early-stage programs leveraging Xeris’ technology platforms, XeriSol® and XeriJect®, for its partners. Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on X, LinkedIn, or Instagram. Forward-Looking Statements Any statements in this press release other than statements of historical fact are forward-looking statements. Forward-looking statements include, but are not limited to, statements about future expectations, plans, opportunities, and prospects for Xeris Biopharma Holdings, Inc. including statements regarding the financial outlook for 2025, including quarterly product revenue, projections regarding total revenue, patients on therapy, positive adjusted EBITDA, company performance in 2026, the potential for growth of revenue, the company’s ability to continue on its current growth trajectory, including its ability to fuel sustained long-term, rapid growth across its business, the market, demand and therapeutic potential of its products and product candidates, the potential utility of its formulation platforms, the advancement of its pipeline (including XP-8121), the timing of the release of its financial results and outlook, and other statements containing the words “achieve,” “anticipate,” “continue,” “expect,” “should,” “will,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on numerous assumptions and assessments made in light of Xeris’ experience and perception of historical trends, current conditions, business strategies, operating environment, future developments, geopolitical factors and other factors it believes appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. The various factors that could cause Xeris’ actual results (including revenue and sales in the near- and long-term), performance or achievements, industry results, market opportunity and developments to differ materially from those expressed in or implied by such forward-looking statements, include, but are not limited to, its financial position and need for financing, including to fund its product development programs or commercialization efforts, whether its products will achieve and maintain market acceptance in a competitive business environment, its reliance on third-party suppliers, including single-source suppliers, its reliance on third parties to conduct clinical trials, the ability of its product candidates to compete successfully with existing and new drugs, its and collaborators’ ability to protect its intellectual property and proprietary technology, the accuracy and completeness of its assumptions and its ability to accurately estimate future financial results and market opportunities, and general macroeconomic and geopolitical conditions, including the possibility of an economic downturn, changes in governmental priorities and resources, announced or implemented tariffs or export controls and market volatility. No assurance can be given that such expectations will be realized and persons reading this communication are, therefore, cautioned not to place undue reliance on these forward-looking statements. Additional risks and information about potential impacts of financial, operational, economic, competitive, regulatory, governmental, technological, and other factors that may affect Xeris can be found in Xeris’ filings, including its most recently filed Annual Report on Form 10-K and subsequent filings with the U.S. Securities and Exchange Commission (SEC), the contents of which are not incorporated by reference into, nor do they form part of, this communication. The risks described herein and in Xeris’ SEC filings are not the only risks the company faces. Additional risks and uncertainties not currently known to it or that it currently deems immaterial may also impact its business operations or financial results. You are encouraged to read its filings with the SEC, available at www.sec.gov and www.xerispharma.com, for a discussion of these and other risks and uncertainties. Forward-looking statements in this communication are based on information available to management, as of the date of this communication and, while the company believes its assumptions are reasonable, actual results may differ materially. Subject to any obligations under applicable law, the company does not undertake any obligation to update any forward-looking statement whether as a result of new information, future developments or otherwise, or to conform any forward-looking statement to actual results, future events, or to changes in expectations. Xeris is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. View source version on businesswire.com: https://www.businesswire.com/news/home/20260108889727/en/ Investor Contact Allison Wey Senior Vice President, Investor Relations and Corporate Communications awey@xerispharma.com Source: Xeris Biopharma Holdings, Inc.

New Delhi: Experts in the pharma industry have raised their concerns over the government's move to notify a minimum import price (MIP) for certain key pharmaceutical inputs to combat aggressive undercutting and dumping from Chinese manufacturers . Experts said a chain-wide MIP on Pen-G, 6-APA and amoxicillin would raise costs across essential medicines, disrupt government tenders and concentrate supply-without clear evidence of dumping or import-led injury. "The country must protect and build its local infrastructure. However, the approach must be measured, so as to not destroy an entire network of MSMEs and significantly increase the cost for life saving antibiotics for the nation's poorest and most vulnerable," said an expert on the condition of anonymity. The government has proposed to impose MIP on Penicillin-G (Pen-G), with possible extension to 6-aminopenicillanic acid (6-APA) and amoxicillin. Penicillin-G is not a standalone product. It is the upstream 'mother molecule' for a wide range of essential antibiotics, feeding into intermediates such as 6-APA, GCLE and 7-ADCA, and into high-volume formulations including amoxicillin, ampicillin, multiple cephalosporins and widely used combinations. "Because of this structure, an MIP at Pen-G-or worse, across Pen-G, 6-APA, amoxicillin-acts as a cost floor across dozens of price-controlled formulations used extensively in primary care and public procurement," he said. The National Pharmaceutical Pricing Authority had earlier in 2019 and 2024 invoked Paragraph 19 of DPCO-to raise ceiling prices for penicillin-family antibiotics after manufacturers reported non-viable economics. "This confirms that essential anti-infectives operate on extremely thin margins even without trade restrictions," another expert said. An analysis of tenders shows that the state government procurement for amoxicillin and key combinations totals about ₹1,012.6 crore at current prices. "If API costs double to the MIP levels under discussion, suppliers face losses of approximately ₹350 crore, rendering multiple contracts non-viable. Past tender data already shows that similar input-cost shocks led to sharp price increases, bidder exits and re-tendering across states," said another expert. He said that data suggested that Pen-G prices have reverted to pre-Covid levels of about $13.5 per kg. Over the last twelve months, India imported approximately 8000 tonnes of Pen-G. In the same period, the country imported around 11,250 tonnes of 6-APA, compared with reported domestic capacity of roughly 3,600 tonnes per annum. "Even after adjusting for exports, domestic requirements materially exceed available capacity. Notably, there has been no meaningful open-market domestic supply of Pen-G or 6-APA in the current financial year, and significant volumes have been transacted with related parties," he added. In 2020, the government launched a production-linked incentive (PLI) scheme to draw investments in the manufacturing of critical raw material from domestic players, as part of efforts to reduce the country's dependence on China and bring pricing stability. However, the Chinese started cutting the prices even further, putting at risk huge investments made by the PLI beneficiaries. "Layering a high MIP on top of PLI risks converting it into permanent protection, weakening efficiency incentives and transferring costs to patients and public budgets. Where a PLI beneficiary shows low-capacity utilisation, high fixed costs and reliance on inter-company financing, the corrective tools should be operational restructuring and scale-up-not a nationwide price floor on essential inputs". By Teena Thacker ,